AHA Comments to DEA on 2019 Controlled Substances Quotas

AHA comments on the Drug Enforcement Administration’s (DEA) notice of proposed rulemaking on aggregate production quotas for Schedule I and II controlled substances.

Key Resources

Related Resources

Advisory
HRSA Finalizes 340B Administrative Dispute Resolution Process
Member
Letter/Comment
AHA Responds to FDA's Proposed Regulation of Diagnostic Tests
Public
Testimony
AHA Statement on "Evaluating Approaches to Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule."
Letter/Comment
AHA Urges Congress to Provide Support to Help Minimize Further Fallout from Change Healthcare Attack
Public
Advisory
Highlights of President Biden’s Executive Order on AI and Its Impact on Health Care
Public
Advisory
CMS Finalizes SNF Disclosure of Ownership Rules, Applies Definitions to Hospital Enrollment
Member